Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC-Reference-Cited by-同舟云学术

Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC

Published:2022-09 Issue: Volume:171 Page:103-114
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Bokhari A.A.,Lai W-Y.,Le A.T.,Gabre J.L.,Chuang T-P.,Fransson S.,Bergman B.,Djos A.,Chen N.,Martinsson T.,Van den Eynden J.,Doebele R.C.,Palmer R.H.,Hallberg B.,Umapathy G.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference72 articles.

1. Lung cancer: diagnosis and management;Collins;Am. Fam. Physician,2007

2. Targeting ALK: Precision Medicine Takes on Drug Resistance;Lin;Cancer Discov.,2017

4. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial;Camidge;J. Thorac. Oncol.,2021

5. Catalog of 5' Fusion Partners in ALK-positive NSCLC Circa 2020;Ou;JTO Clin. Res. Rep.,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib;Frontiers in Oncology;2024-01-09

2. ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression;Proceedings of the National Academy of Sciences;2023-02-15